Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004560.pdf
0001415889-23-004560.rtf
0001415889-23-004560.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004564.pdf
0001415889-23-004564.rtf
0001415889-23-004564.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004561.pdf
0001415889-23-004561.rtf
0001415889-23-004561.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004565.pdf
0001415889-23-004565.rtf
0001415889-23-004565.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004566.pdf
0001415889-23-004566.rtf
0001415889-23-004566.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004257.pdf
0001415889-23-004257.rtf
0001415889-23-004257.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004261.pdf
0001415889-23-004261.rtf
0001415889-23-004261.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004258.pdf
0001415889-23-004258.rtf
0001415889-23-004258.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004259.pdf
0001415889-23-004259.rtf
0001415889-23-004259.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-004263.pdf
0001415889-23-004263.rtf
0001415889-23-004263.xls